Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Global Adipose Tissue-derived Stem Cell Therapy Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Adipose Tissue-derived Stem Cell Therapy Revenue
  • 1.4 Covid-19 Implications on Market by Type
    • 1.4.1 Global Adipose Tissue-derived Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Autologous Stem Cells
    • 1.4.3 Allogeneic Stem Cells
  • 1.5 Market by Application
    • 1.5.1 Global Adipose Tissue-derived Stem Cell Therapy Market Share by Application: 2020 VS 2026
    • 1.5.2 Therapeutic Application
    • 1.5.3 Research Application
  • 1.6 Coronavirus Disease 2019 (Covid-19): Adipose Tissue-derived Stem Cell Therapy Industry Impact
    • 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.6.2 Covid-19 Impact: Commodity Prices Indices
    • 1.6.3 Covid-19 Impact: Global Major Government Policy
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends

  • 2.1 Covid-19 Implications on Global Adipose Tissue-derived Stem Cell Therapy Market Perspective (2015-2026)
  • 2.2 Covid-19 Implications on Global Adipose Tissue-derived Stem Cell Therapy Growth Trends by Regions
    • 2.2.1 Adipose Tissue-derived Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Adipose Tissue-derived Stem Cell Therapy Historic Market Share by Regions (2015-2020)
    • 2.2.3 Adipose Tissue-derived Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Adipose Tissue-derived Stem Cell Therapy Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Adipose Tissue-derived Stem Cell Therapy Players (Opinion Leaders)

3 Covid-19 Implications on Competition Landscape by Key Players

  • 3.1 Global Top Adipose Tissue-derived Stem Cell Therapy Players by Market Size
    • 3.1.1 Global Top Adipose Tissue-derived Stem Cell Therapy Players by Revenue (2015-2020)
    • 3.1.2 Global Adipose Tissue-derived Stem Cell Therapy Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Adipose Tissue-derived Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Adipose Tissue-derived Stem Cell Therapy Market Concentration Ratio
    • 3.2.1 Global Adipose Tissue-derived Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Adipose Tissue-derived Stem Cell Therapy Revenue in 2019
  • 3.3 Adipose Tissue-derived Stem Cell Therapy Key Players Head office and Area Served
  • 3.4 Key Players Adipose Tissue-derived Stem Cell Therapy Product Solution and Service
  • 3.5 Date of Enter into Adipose Tissue-derived Stem Cell Therapy Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Covid-19 Implications on Market Size by Type (2015-2026)

  • 4.1 Global Adipose Tissue-derived Stem Cell Therapy Historic Market Size by Type (2015-2020)
  • 4.2 Global Adipose Tissue-derived Stem Cell Therapy Forecasted Market Size by Type (2021-2026)

5 Covid-19 Implications on Market Size by Application (2015-2026)

  • 5.1 Global Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)
  • 5.2 Global Adipose Tissue-derived Stem Cell Therapy Forecasted Market Size by Application (2021-2026)

6 North America Impact of COVID-19

  • 6.1 North America Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 6.2 Adipose Tissue-derived Stem Cell Therapy Key Players in North America (2019-2020)
  • 6.3 North America Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 6.4 North America Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

7 Europe Impact of COVID-19

  • 7.1 Europe Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 7.2 Adipose Tissue-derived Stem Cell Therapy Key Players in Europe (2019-2020)
  • 7.3 Europe Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 7.4 Europe Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

8 China Impact of COVID-19

  • 8.1 China Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 8.2 Adipose Tissue-derived Stem Cell Therapy Key Players in China (2019-2020)
  • 8.3 China Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 8.4 China Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

9 Japan Impact of COVID-19

  • 9.1 Japan Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 9.2 Adipose Tissue-derived Stem Cell Therapy Key Players in Japan (2019-2020)
  • 9.3 Japan Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 9.4 Japan Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

10 Southeast Asia Impact of COVID-19

  • 10.1 Southeast Asia Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 10.2 Adipose Tissue-derived Stem Cell Therapy Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

11 India Impact of COVID-19

  • 11.1 India Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 11.2 Adipose Tissue-derived Stem Cell Therapy Key Players in India (2019-2020)
  • 11.3 India Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 11.4 India Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

12 Central & South America Impact of COVID-19

  • 12.1 Central & South America Adipose Tissue-derived Stem Cell Therapy Market Size (2015-2020)
  • 12.2 Adipose Tissue-derived Stem Cell Therapy Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Adipose Tissue-derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 12.4 Central & South America Adipose Tissue-derived Stem Cell Therapy Market Size by Application (2015-2020)

13Key Players Profiles

  • 13.1 AlloCure
    • 13.1.1 AlloCure Company Details
    • 13.1.2 AlloCure Business Overview and Its Total Revenue
    • 13.1.3 AlloCure Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.1.4 AlloCure Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020))
    • 13.1.5 AlloCure Recent Development and Reaction to COVID-19
  • 13.2 Antria
    • 13.2.1 Antria Company Details
    • 13.2.2 Antria Business Overview and Its Total Revenue
    • 13.2.3 Antria Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.2.4 Antria Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.2.5 Antria Recent Development and Reaction to COVID-19
  • 13.3 Celgene Corporation
    • 13.3.1 Celgene Corporation Company Details
    • 13.3.2 Celgene Corporation Business Overview and Its Total Revenue
    • 13.3.3 Celgene Corporation Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.3.4 Celgene Corporation Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.3.5 Celgene Corporation Recent Development and Reaction to COVID-19
  • 13.4 Cellleris
    • 13.4.1 Cellleris Company Details
    • 13.4.2 Cellleris Business Overview and Its Total Revenue
    • 13.4.3 Cellleris Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.4.4 Cellleris Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.4.5 Cellleris Recent Development and Reaction to COVID-19
  • 13.5 Corestem
    • 13.5.1 Corestem Company Details
    • 13.5.2 Corestem Business Overview and Its Total Revenue
    • 13.5.3 Corestem Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.5.4 Corestem Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.5.5 Corestem Recent Development and Reaction to COVID-19
  • 13.6 Cytori Therapeutics
    • 13.6.1 Cytori Therapeutics Company Details
    • 13.6.2 Cytori Therapeutics Business Overview and Its Total Revenue
    • 13.6.3 Cytori Therapeutics Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.6.4 Cytori Therapeutics Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.6.5 Cytori Therapeutics Recent Development and Reaction to COVID-19
  • 13.7 Intrexon
    • 13.7.1 Intrexon Company Details
    • 13.7.2 Intrexon Business Overview and Its Total Revenue
    • 13.7.3 Intrexon Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.7.4 Intrexon Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.7.5 Intrexon Recent Development and Reaction to COVID-19
  • 13.8 Mesoblast
    • 13.8.1 Mesoblast Company Details
    • 13.8.2 Mesoblast Business Overview and Its Total Revenue
    • 13.8.3 Mesoblast Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.8.4 Mesoblast Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.8.5 Mesoblast Recent Development and Reaction to COVID-19
  • 13.9 Pluristem Therapeutics
    • 13.9.1 Pluristem Therapeutics Company Details
    • 13.9.2 Pluristem Therapeutics Business Overview and Its Total Revenue
    • 13.9.3 Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.9.4 Pluristem Therapeutics Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.9.5 Pluristem Therapeutics Recent Development and Reaction to COVID-19
  • 13.10 Tissue Genesis
    • 13.10.1 Tissue Genesis Company Details
    • 13.10.2 Tissue Genesis Business Overview and Its Total Revenue
    • 13.10.3 Tissue Genesis Adipose Tissue-derived Stem Cell Therapy Introduction
    • 13.10.4 Tissue Genesis Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 13.10.5 Tissue Genesis Recent Development and Reaction to COVID-19
  • 13.11 BioRestorative Therapies
    • 10.11.1 BioRestorative Therapies Company Details
    • 10.11.2 BioRestorative Therapies Business Overview and Its Total Revenue
    • 10.11.3 BioRestorative Therapies Adipose Tissue-derived Stem Cell Therapy Introduction
    • 10.11.4 BioRestorative Therapies Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 10.11.5 BioRestorative Therapies Recent Development and Reaction to COVID-19
  • 13.12 Celltex Therapeutics Corporation
    • 10.12.1 Celltex Therapeutics Corporation Company Details
    • 10.12.2 Celltex Therapeutics Corporation Business Overview and Its Total Revenue
    • 10.12.3 Celltex Therapeutics Corporation Adipose Tissue-derived Stem Cell Therapy Introduction
    • 10.12.4 Celltex Therapeutics Corporation Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 10.12.5 Celltex Therapeutics Corporation Recent Development and Reaction to COVID-19
  • 13.13 iXCells Biotechnologies
    • 10.13.1 iXCells Biotechnologies Company Details
    • 10.13.2 iXCells Biotechnologies Business Overview and Its Total Revenue
    • 10.13.3 iXCells Biotechnologies Adipose Tissue-derived Stem Cell Therapy Introduction
    • 10.13.4 iXCells Biotechnologies Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 10.13.5 iXCells Biotechnologies Recent Development and Reaction to COVID-19
  • 13.14 Pluristem Therapeutics
    • 10.14.1 Pluristem Therapeutics Company Details
    • 10.14.2 Pluristem Therapeutics Business Overview and Its Total Revenue
    • 10.14.3 Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Introduction
    • 10.14.4 Pluristem Therapeutics Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 10.14.5 Pluristem Therapeutics Recent Development and Reaction to COVID-19
  • 13.15 Cyagen
    • 10.15.1 Cyagen Company Details
    • 10.15.2 Cyagen Business Overview and Its Total Revenue
    • 10.15.3 Cyagen Adipose Tissue-derived Stem Cell Therapy Introduction
    • 10.15.4 Cyagen Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 10.15.5 Cyagen Recent Development and Reaction to COVID-19
  • 13.16 Lonza
    • 10.16.1 Lonza Company Details
    • 10.16.2 Lonza Business Overview and Its Total Revenue
    • 10.16.3 Lonza Adipose Tissue-derived Stem Cell Therapy Introduction
    • 10.16.4 Lonza Revenue in Adipose Tissue-derived Stem Cell Therapy Business (2015-2020)
    • 10.16.5 Lonza Recent Development and Reaction to COVID-19

14Analyst's Viewpoints/Conclusions

    15Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Adipose tissue stem cells (ASCs), known as multipotent stem cells, are most commonly used in the clinical applications in recent years.
    Market Analysis and Insights: Global Adipose Tissue-derived Stem Cell Therapy Market
    Prior to COVID-19, the market for Adipose Tissue-derived Stem Cell Therapy was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Adipose Tissue-derived Stem Cell Therapy is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Adipose Tissue-derived Stem Cell Therapy market.

    Global Adipose Tissue-derived Stem Cell Therapy Scope and Market Size
    Adipose Tissue-derived Stem Cell Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Adipose Tissue-derived Stem Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
    Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Adipose Tissue-derived Stem Cell Therapy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
    This report also analyzes the impact of Coronavirus COVID-19 on the Adipose Tissue-derived Stem Cell Therapy industry.
    The following players are covered in this report:
    AlloCure
    Antria
    Celgene Corporation
    Cellleris
    Corestem
    Cytori Therapeutics
    Intrexon
    Mesoblast
    Pluristem Therapeutics
    Tissue Genesis
    BioRestorative Therapies
    Celltex Therapeutics Corporation
    iXCells Biotechnologies
    Pluristem Therapeutics
    Cyagen
    Lonza
    Adipose Tissue-derived Stem Cell Therapy Breakdown Data by Type
    Autologous Stem Cells
    Allogeneic Stem Cells
    Adipose Tissue-derived Stem Cell Therapy Breakdown Data by Application
    Therapeutic Application
    Research Application
    Buy now